---
layout: minimal-medicine
title: Ziv-Aflibercept
---

# Ziv-Aflibercept
### Generic Name
Ziv-aflibercept

### Usage

Ziv-aflibercept is primarily used in the treatment of metastatic colorectal cancer.  Specifically, it's indicated for patients whose cancer has become resistant to or progressed after treatment with an oxaliplatin-containing regimen. In this setting, Ziv-aflibercept is administered in combination with FOLFIRI (a chemotherapy regimen consisting of fluorouracil, leucovorin, and irinotecan).  While not officially approved for this purpose, Ziv-aflibercept has also shown some use in managing symptomatic ascites (fluid buildup in the abdomen) caused by malignant ovarian cancer.  This off-label use should only be considered under the strict guidance of a qualified oncologist.


### Dosage

**Adult Dosage:** For metastatic colorectal cancer, the typical dose is 4 mg/kg (based on actual body weight) administered intravenously (IV) every two weeks. This is always given in combination with the FOLFIRI chemotherapy regimen, with Ziv-aflibercept administered *before* the chemotherapy components on the treatment day. Treatment continues until the disease progresses or unacceptable side effects occur.  For off-label use in symptomatic ascites due to malignant ovarian cancer, a similar 4 mg/kg IV dose every two weeks is often employed, typically for 2-6 months.

**Pediatric Dosage:** The safety and effectiveness of Ziv-aflibercept in children have not been established.

**Dosage Adjustments:**  Several factors can influence Ziv-aflibercept dosage.  Mild to moderate hepatic impairment generally doesn't require dose adjustment, but severe impairment necessitates careful consideration and may necessitate a change in treatment strategy.  Renal impairment prior to treatment initiation also typically doesn't require an immediate dose adjustment. However,  development of proteinuria (protein in the urine) during treatment may lead to temporary withholding of the drug or a permanent dose reduction.  Severe renal complications like nephrotic syndrome or thrombotic microangiopathy necessitate immediate discontinuation of Ziv-aflibercept.  Other toxicities like arterial thrombotic events, fistula formation, severe hemorrhage, uncontrolled hypertension, or certain types of neutropenia can all necessitate dose adjustments or complete discontinuation.  Patients undergoing elective surgery should temporarily discontinue Ziv-aflibercept.  Specific guidelines for dosage adjustments should be carefully discussed with a healthcare professional.


### Side Effects

**Common Side Effects (>10%):**

* Fatigue
* Headache
* Voice disorders
* Hypertension
* Abdominal pain
* Decreased appetite
* Diarrhea
* Stomatitis (mouth sores)
* Upper abdominal pain
* Palmar-plantar erythrodysesthesia (hand-foot syndrome)
* Weight loss
* Proteinuria
* Hemorrhage
* Leukopenia (low white blood cell count)
* Neutropenia (low neutrophil count)
* Thrombocytopenia (low platelet count)
* Increased serum ALT and AST levels (liver enzymes)
* Antibody development
* Asthenia (weakness)
* Increased serum creatinine
* Dyspnea (shortness of breath)
* Epistaxis (nosebleed)
* Infection


**Less Common but Serious Side Effects (<10%):**

* Arterial and venous thromboembolic events (blood clots)
* Gastrointestinal hemorrhage
* Severe hypersensitivity reactions
* GI perforation (hole in the gastrointestinal tract)
* Hypertensive crisis
* Nephrotic syndrome
* Thrombotic microangiopathy
* Reversible posterior leukoencephalopathy syndrome (RPLS)
* Impaired wound healing


**Note:** This list is not exhaustive.  Any new or worsening symptoms should be reported to a healthcare provider immediately.


### How it Works

Ziv-aflibercept is a targeted therapy that works by inhibiting the vascular endothelial growth factor (VEGF) pathway. VEGF is a protein that plays a crucial role in angiogenesis â€“ the formation of new blood vessels.  Tumors rely on angiogenesis to grow and spread. Ziv-aflibercept acts as a decoy receptor, binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing them from activating VEGF receptors on the surface of endothelial cells.  By blocking the VEGF pathway, Ziv-aflibercept restricts tumor blood supply, reducing tumor growth and potentially leading to tumor regression.


### Precautions

* **Pregnancy:** Ziv-aflibercept can cause harm to a developing fetus.  Women of reproductive potential should use effective contraception during treatment and for one month after the final dose.
* **Lactation:** It is unknown whether Ziv-aflibercept is excreted in breast milk; breastfeeding should be avoided during treatment and for one month after the last dose.
* **Drug Interactions:**  While not extensively documented in this context, interactions with other medications are possible.  It is crucial to inform your healthcare provider about all medications, supplements, and herbal remedies being taken.
* **Renal and Hepatic Impairment:** As previously discussed, patients with renal or hepatic impairment require careful monitoring and potential dose adjustments.
* **Older Adults:** Elderly patients may be at increased risk for certain side effects, such as diarrhea and dehydration, and require closer monitoring.
* **Wound Healing:** Ziv-aflibercept can impair wound healing.  Patients should avoid elective surgery while on treatment.
* **Hypersensitivity:** Although rare, severe hypersensitivity reactions have been reported.  Patients should be monitored closely for any signs of allergic reactions.

### FAQs

* **Q: How long does it take for Ziv-aflibercept to work?** A: The time it takes to see a response varies significantly depending on individual factors and disease response.  Clinical effects are often monitored over time through imaging and other assessments.

* **Q: How is Ziv-aflibercept stored?** A:  Refer to the specific storage instructions provided with your medication.

* **Q: What should I do if I miss a dose?** A: Contact your healthcare provider immediately for guidance on missed doses; do not attempt to adjust the dosing schedule independently.

* **Q: Can I drink alcohol while taking Ziv-aflibercept?** A: It is always best to consult with your doctor about alcohol consumption while on any medication.  Alcohol may exacerbate some of the side effects, particularly related to the liver or gastrointestinal system.

* **Q: Are there long-term effects associated with Ziv-aflibercept?** A: Like any medication, Ziv-aflibercept may have long-term effects.  Regular check-ups and monitoring are crucial to detect and manage any potential long-term issues.  This information should be discussed with your healthcare provider.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a qualified healthcare professional for diagnosis, treatment, and management of any medical condition. The provided information reflects currently available data; always consult the most up-to-date prescribing information for the most accurate and complete details.
